Share

Alchemist Ltd. Stocks

0Last Updated 23.03.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₹ 456178.7916

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Alchemist Limited manufactures and trades in chemicals and pharmaceutical formulations in India. The company operates in Agri Business; and Pharma, Chemical, and Minerals segments. It offers pharmaceutical products, such as Anemi-XT for iron deficiency, Valcal-M for calcium deficiency, and IGTG FORTE for weak immunity, as well as in the therapy areas of immune enhancer, nutraceutical, antibacterial, gastrointestinal, pain reliever, anti-allergic, anti-cold, steroids, enzymes, supplements, CNS, etc. The company is also involved in the agriculture and allied activities comprising floriculture activities. In addition, it offers steel wires that are used to manufacture barbed and razor wires, wire mesh, and chain link fencing products for poultry; and other wire fencing for nonresidential and residential building applications. Alchemist Limited was incorporated in 1988 and is headquartered in New Delhi, India.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E. Editor's note: P/

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks